MTRAC issued a new Commissioning Support review in June 2014. The review covers avanafil.
The avanafil (Spedra®) summary advises that this drug is suitable for restricted prescribing in primary care within the existing regulations imposed by the Department of Health for prescribing treatments for erectile dysfunction. The review notes that this medicine has relatively weak evidence because the currently published trials compared this agent to placebo rather and against an active PDE-5 inhibitor comparator such as sildenafil.
Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.
|« Drug Safety Update - May 2014||Update to Controlled Drugs Legislation »|